Insider Selling: Axon Enterprise (NASDAQ:AXON) CFO Sells $1,160,000.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) CFO Brittany Bagley sold 2,000 shares of Axon Enterprise stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the sale, the chief financial officer owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This represents a 1.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Brittany Bagley also recently made the following trade(s):

• On Monday, November 10th, Brittany Bagley sold 2,500 shares of Axon Enterprise stock. The stock was sold at an average price of $610.00, for a total value of $1,525,000.00.
• On Monday, September 29th, Brittany Bagley sold 5,000 shares of Axon Enterprise stock. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00.
• On Monday, September 15th, Brittany Bagley sold 870 shares of Axon Enterprise stock. The shares were sold at an average price of $773.25, for a total transaction of $672,727.50.

Axon Enterprise Trading Down 2.9%

Shares of NASDAQ:AXON opened at $564.28 on Monday. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $44.53 billion, a PE ratio of 178.57, a P/E/G ratio of 129.60 and a beta of 1.40. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91. The firm has a fifty day moving average price of $623.94 and a 200 day moving average price of $713.90.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The business’s revenue was up 30.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.45 EPS. Analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently made changes to their positions in the business. TCI Wealth Advisors Inc. bought a new stake in Axon Enterprise during the second quarter worth about $214,000. Wealthedge Investment Advisors LLC raised its stake in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 775 shares in the last quarter. Jaffetilchin Investment Partners LLC boosted its holdings in shares of Axon Enterprise by 11.7% in the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 5,938 shares of the biotechnology company’s stock valued at $4,916,000 after buying an additional 624 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 3.5% in the second quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock valued at $7,399,515,000 after buying an additional 305,252 shares in the last quarter. Finally, Duncker Streett & Co. Inc. increased its holdings in Axon Enterprise by 3.2% during the second quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock worth $12,006,000 after buying an additional 448 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research note on Monday, September 29th. Piper Sandler decreased their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 8th. Finally, UBS Group lowered their target price on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $815.00.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.